Prospective and challenges of islet transplantation for the therapy of autoimmune diabetes

Pancreas

Volumn 32, Issue 3, 2006, Pages 231-243

  Balamurugan, A N ^a,b   Bottino, Rita ^b   Giannoukakis, Nick ^b,c   Smetanka, Cynthia ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Human islet transplantation; Immunosuppression; Islet isolation

Indexed keywords

ALEMTUZUMAB; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ASCORBIC ACID; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOSPORIN; DACLIZUMAB; ETANERCEPT; FINGOLIMOD; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; LYMPHOBLAST ANTIBODY; OKT 3; PYRIDOXINE; RAPAMYCIN; RETINOL; TACROLIMUS; VALGANCICLOVIR;

ADULT; ALLOGRAFT; ALLOTRANSPLANTATION; ANEMIA; ARTHRALGIA; AUTOIMMUNE DISEASE; BLEEDING; DIABETES MELLITUS; DIABETIC PATIENT; DIARRHEA; DIZZINESS; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENCE; INSULIN RELEASE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MUSCULOSKELETAL PAIN; PANCREAS FUNCTION; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; REVIEW; SIDE EFFECT; SURGICAL PATIENT; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TREMOR; WOUND HEALING; AUTOIMMUNITY; AUTOTRANSPLANTATION; CELL SEPARATION; GRAFT REJECTION; INSULIN DEPENDENT DIABETES MELLITUS; METHODOLOGY; ORGAN PRESERVATION; RECURRENT DISEASE; TRANSPLANTATION;

AUTOIMMUNITY; CELL SEPARATION; DIABETES MELLITUS, TYPE 1; GRAFT REJECTION; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; ORGAN PRESERVATION; PROSPECTIVE STUDIES; RECURRENCE; TISSUE AND ORGAN PROCUREMENT; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33646692209     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpa.0000203961.16630.2f     Document Type: Review

References (127)

1. Onkamo P, Vaananen S, Karvonen M, et al. Worldwide increase in incidence of Type I diabetes - the analysis of the data on published incidence trends. Diabetologia. 1999;42:1395-1403.
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
3. Trucco M. Regeneration of the pancreatic beta cell. J Clin Invest. 2005;115:5-12.
4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-986.
5. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1997;46(2):271-286.
6. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:99-111.
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
8. Sutherland DE. International Pancreas Transplant Registry (IPTR), 2003 Annual Report. 2003.
9. Sutherland DE, Gruessner RW, Dunn DL, et al. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg. 2001;233:463-501.
10. Sutherland DE. Current status of beta-cell replacement therapy (pancreas and islet transplantation) for treatment of diabetes mellitus. Transplant Proc. 2003;35:1625-1627.
11. Bottino R, Trucco M, Balamurugan AN, et al. Pancreas and islet cell transplantation. Best Pract Res Clin Gastroenterol. 2002;16:457-474.
12. Bottino R, Balamurugan AN, Giannoukakis N, et al. Islet/pancreas transplantation: challenges for pediatrics. Pediatr Diabetes. 2002;3:210-223.
13. Gruessner RW. Immunosuppression after pancreas transplantation. Transplant Proc. 2005;37:1663-1666.
14. Shapiro AM, Lakey JR, Paty BW, et al. Strategic opportunities in clinical islet transplantation. Transplantation. 2005;79:1304-1307.
15. Position Statement: Pancreas transplantation for patients with type 1 diabetes: American Diabetes Association. Diabetes Care. 2004;27(Supl 1):S105.
16. Berney T, Buhler LH, Morel P. Pancreas allocation in the era of islet transplantation. Transpl Int. 2005;18:763-767.
17. Bertuzzi F, Secchi A, Di Carlo V. Islet transplantation in type 1 diabetic patients. Transplant Proc 2004;36:603-604.
18. Kemp CB, Knight MJ, Scharp DW, et al. Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats. Diabetologia. 1973;9:486-491.
19. Najarian JS, Sutherland DE, Matas AJ, et al. Human islet transplantation: a preliminary report. Transplant Proc. March 1977;9(1):233-236.
20. Najarian JS, Sutherland DE, Matas AJ, et al. Human islet autotransplantation following pancreatectomy. Transplant Proc. 1979;11:336-340.
21. Morrison CP, Wemyss-Holden SA, Dennison AR, et al. Islet yield remains a problem in islet autotransplantation. Arch Surg. 2002;137:80-83.
22. Oberholzer J, Triponez F, Mage R, et al. Human islet transplantation: lessons from 13 autologous and 13 allogeneic transplantations. Transplantation. 2000;69:1115-1123.
23. Gruessner RW, Sutherland DE, Dunn DL, et al. Transplant options for patients undergoing total pancreatectomy for chronic pancreatitis. J Am Coll Surg. 2004;198:559-567.
24. Bretzel R, Brendel M, Hering B. International Islet Transplantat Registry, Newsletter # 8. 1999.
25. Bretzel R, Brendel M, Hering B. International Islet Transplant Registry, Newsletter #9. 2001;8:1.
26. Robertson RP, Lanz KJ, Sutherland DE, et al. Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis. Diabetes. 2001;50:47-50.
27. Ricordi C, Lacy PE, Scharp DW. Automated islet isolation from human pancreas. Diabetes. 1989;38(Suppl 1):140-142.
28. Tzakis AG, Ricordi C, Alejandro R, et al. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet. 1990;336:402-405.
29. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230-238.
30. Robertson RP. Islet transplantation as a treatment for diabetes - a work in progress. N Engl J Med. 2004;350:694-705.
31. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54:2060-2069.
32. Connolly JE. Pancreatic whole organ transplantation. Surg Clin North Am. 1978;58:383-390.
33. Gunnarsson R, Bottazzo GF, Freedman ZR, et al. Allogeneic rejection or recurrence of autoimmunity as the cause of immune destruction of pancreatic grafts. Transplant Proc. 1980;12:112-113.
34. Santamaria P, Nakhleh RE, Sutherland DE, et al. Characterization of T lymphocytes infiltrating human pancreas allograft affected by isletitis and recurrent diabetes. Diabetes. 1992;41:53-61.
35. Stegall MD, Lafferty KJ, Kam I, et al. Evidence of recurrent autoimmunity in human allogeneic islet transplantation. Transplantation. 1996;61:1272-1274.
36. Roep BO, Stobbe I, Duinkerken G, et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes. 1999;48:484-490.
37. Brooks-Worrell BM, Peterson KP, Peterson CM, et al. Reactivation of type 1 diabetes in patients receiving human fetal pancreatic tissue transplants without immunosuppression. Transplantation. 2000;69:1824-1829.
38. Petruzzo P, Andreelli F, McGregor B, et al. Evidence of recurrent type I diabetes following HLA-mismatched pancreas transplantation. Diabetes Metab. 2000;26:215-218.
39. Gottlieb PA, Berrios JP, Mariani G, et al. Autoimmune destruction of islets transplanted into RT6-depleted diabetes-resistant BB/Wor rats. Diabetes. 1990;39:643-645.
40. Wang T, Singh B, Warnock GL, et al. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy. Diabetes. 1992;41:114-117.
41. Makhlouf L, Kishimoto K, Smith RN, et al. The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade. Diabetes. 2002;51:3202-3210.
42. Makhlouf L, Yamada A, Ito T, et al. Allorecognition and effector pathways of islet allograft rejection in normal versus nonobese diabetic mice. J Am Soc Nephrol. 2003;14:2168-2175.
43. Pearson T, Markees TG, Serreze DV, et al. Genetic disassociation of autoimmunity and resistance to costimulation blockade-induced transplantation tolerance in nonobese diabetic mice. J Immunol. 2003;171:185-195.
44. Markmann JF, Jacobson JD, Brayman KL, et al. Prevention of recurrent diabetes in BB rats after islet transplantation by monoclonal antibody therapy. Diabetes. January 1989;38(Suppl 1):165-167.
45. Maki T, Ichikawa T, Blanco R, et al. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Natl Acad Sci U S A. 1992;89:3434-3438.
46. Guo Z, Wu T, Kirchhof N, et al. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection. Transplantation. 2001;71:1656-1665.
47. Makhlouf L, Grey ST, Dong V, et al. Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice. Transplantation. 2004;77:990-997.
48. Kover KL, Geng Z, Hess D, et al. CD40/154 blockade and rejection of islet allografts in the streptozotocin and autoimmune diabetic rat. Pediatr Diabetes. 2001;2:178-183.
49. Molano RD, Pileggi A, Berney T, et al. Prolonged islet allograft survival in diabetic NOD mice by targeting CD45RB and CD154. Diabetes. 2003;52:957-964.
50. Georgiou HM, Constantinou D, Mandel TE. Prevention of autoimmunity in nonobese diabetic (NOD) mice by neonatal transfer of allogeneic thymic macrophages. Autoimmunity. 1995;21:89-97.
51. Li H, Kaufman CL, Ildstad ST. Allogeneic chimerism induces donor-specific tolerance to simultaneous islet allografts in nonobese diabetic mice. Surgery. 1995;118:192-197.
52. Bartlett ST, Schweitzer EJ, Kuo PC, et al. Prevention of autoimmune islet allograft destruction by engraftment of donor T cells. Transplantation. 1997;63:299-303.
53. Seung E, Iwakoshi N, Woda BA, et al. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood. 2000;95:2175-2182.
54. Beilhack GF, Scheffold YC, Weissman IL, et al. Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Diabetes. 2003;52:59-68.
55. Nikolic B, Takeuchi Y, Leykin I, et al. Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity. Diabetes. 2004;53:376-383.
56. Posselt AM, Naji A, Roark JH, et al. Intrathymic islet transplantation in the spontaneously diabetic BB rat. Ann Surg. 1991;214:363-371.
57. Nomura Y, Mullen Y, Stein E. Syngeneic islets transplanted into the thymus of newborn mice prevent diabetes and reduce insulitis in the NOD mouse. Transplant Proc. 1993;25:963-964.
58. Molano RD, Pileggi A, Berney T, et al. Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody. Transplantation. 2003;75:1812-1819.
59. Kaufman DB, Morel P, Condie R, et al. Beneficial and detrimental effects of RBC-adsorbed antilymphocyte globulin and prednisone on purified canine islet autograft and allograft function. Transplantation. 1991;51:37-42.
60. Ozmen L, Ekdahl KN, Elgue G, et al. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes. 2002;51:1779-1784.
61. Contreras JL, Eckstein C, Smyth CA, et al. Brain death significantly reduces isolated pancreatic islet yields and functionality in vitro and in vivo after transplantation in rats. Diabetes. 2003;52:2935-2942.
62. Sollinger HW, Vernon WB, D'Alessandro AM, et al. Combined liver and pancreas procurement with Belzer-UW solution. Surgery. 1989;106:685-690. discussion 690-681.
63. Marsh CL, Perkins JD, Sutherland DE, et al. Combined hepatic and pancreaticoduodenal procurement for transplantation. Surg Gynecol Obstet. 1989;168:254-258.
64. Nakazato PZ, Concepcion W, Bry W, et al. Total abdominal evisceration: an en bloc technique for abdominal organ harvesting. Surgery. 1992;111:37-47.
65. Lakey JR, Kneteman NM, Rajotte RV, et al. Effect of core pancreas temperature during cadaveric procurement on human islet isolation and functional viability. Transplantation. April 15, 2002;73:1106-1110.
66. Lakey JR, Burridge PW, Shapiro AM. Technical aspects of islet preparation and transplantation. Transpl Int. 2003;16:613-632.
67. Matsumoto S, Kuroda Y. Perfluorocarbon for organ preservation before transplantation. Transplantation. 2002;74:1804-1809.
68. Matsumoto S. Clinical application of perfluorocarbons for organ preservation. Artif Cells Blood Substit Immobil Biotechnol. 2005;33:75-82.
69. Kuroda Y, Kawamura T, Suzuki Y, et al. A new, simple method for cold storage of the pancreas using perfluorochemical. Transplantation. 1988;46:457-460.
70. Matsumoto S, Kandaswamy R, Sutherland DE, et al. Clinical application of the two-layer (University of Wisconsin solution/perfluorochemical plus O2) method of pancreas preservation before transplantation. Transplantation. 2000;70:771-774.
71. Hering BJ, Matsumoto I, Sawada T, et al. Impact of two-layer pancreas preservation on islet isolation and transplantation. Transplantation. 2002;74:1813-1816.
72. Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant. 2004;4:390-401.
73. Ricordi C, Fraker C, Szust J, et al. Improved human islet isolation outcome from marginal donors following addition of oxygenated perfluorocarbon to the cold-storage solution. Transplantation. 2003;75:1524-1527.
74. Markmann JF, Deng S, Desai NM, et al. The use of non-heart-beating donors for isolated pancreatic islet transplantation. Transplantation. 2003;75:1423-1429.
75. Tsujimura T, Kuroda Y, Avila JG, et al. Influence of pancreas preservation on human islet isolation outcomes: impact of the two-layer method. Transplantation. 2004;78:96-100.
76. Lakey JR, Warnock GL, Shapiro AM, et al. Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplant. 1999;8:285-292.
77. Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes. 1967;16:35-39.
78. Warnock GL, Cattral MS, Rajotte RV. Normoglycemia after implantation of purified islet cells in dogs. Can J Surg. 1988;31:421-426.
79. Ricordi C, Finke EH, Lacy PE. A method for the mass isolation of islets from the adult pig pancreas. Diabetes. 1986;35:649-653.
80. Gray DW, Warnock GL, Sutton R, et al. Successful autotransplantation of isolated islets of Langerhans in the cynomolgus monkey. Br J Surg. 1986;73:850-853.
81. Gray DW, McShane P, Grant A, et al. A method for isolation of islets of Langerhans from the human pancreas. Diabetes. 1984;33:1055-1061.
82. Wolters GH, Vos-Scheperkeuter GH, van Deijnen JH, et al. An analysis of the role of collagenase and protease in the enzymatic dissociation of the rat pancreas for islet isolation. Diabetologia. 1992; 35:735-742.
83. Wolters GH, van Suylichem PT, van Deijnen JH, et al. Factors influencing the isolation process of islets of Langerhans. Horm Metab Res Suppl. 1990;25:20-26.
84. Eckhardt T, Jahr H, Federlin K, et al. Endotoxin impairs the engraftment of rat islets transplanted beneath the kidney capsule of C57BL/6-mice. J Mol Med. 1999;77:123-125.
85. Jahr H, Pfeiffer G, Hering BJ, et al. Endotoxin-mediated activation of cytokine production in human PBMCs by collagenase and Ficoll. J Mol Med. 1999;77:118-120.
86. Vargas F, Vives-Pi M, Somoza N, et al. Endotoxin contamination may be responsible for the unexplained failure of human pancreatic islet transplantation. Transplantation. 1998;65:722-727.
87. Lakey JR, Helms LM, Kin T, et al. Serine-protease inhibition during islet isolation increases islet yield from human pancreases with prolonged ischemia. Transplantation. 2001;72:565-570.
88. Bucher P, Mathe Z, Bosco D, et al. Serva collagenase NB1: a new enzyme preparation for human islet isolation. Transplant Proc. 2004;36:1143-1144.
89. Bucher P, Mathe Z, Morel P, et al. Assessment of a novel two-component enzyme preparation for human islet isolation and transplantation. Transplantation. 2005;79:91-97.
90. Lake SP, Bassett PD, Larkins A, et al. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes. 1989;38:143-145.
91. Gray DW. The role of exocrine tissue in pancreatic islet transplantation. Transpl Int. 1989;2:41-45.
92. Scharp DW, Kemp CB, Knight MJ, et al. The use of Ficoll in the preparation of viable islets of Langerhans from the rat pancreas. Transplantation. 1973;16:686-689.
93. Lake SP, Anderson J, Chamberlain J, et al. Bovine serum albumin density gradient isolation of rat pancreatic islets. Transplantation. 1987;43:805-808.
94. Lakey JR, Cavanagh TJ, Zieger MA. A prospective comparison of discontinuous EuroFicoll and EuroDextran gradients for islet purification. Cell Transplant. 1998;7:479-487.
95. Tze WI, Wong FC, Tingle AJ. The use of hypaque-Ficoll in the isolation of pancreatic islets in rats. Transplantation. 1976;22:201-205.
96. Scharp DW, Lacy PE, Finke E, et al. Low-temperature culture of human islets isolated by the distention method and purified with Ficoll or Percoll gradients. Surgery. 1987;102:869-879.
97. van Suylichem PT, Wolters GH, van Schilfgaarde R. The efficacy of density gradients for islet purification: a comparison of seven density gradients. Transpl Int. 1990;3:156-161.
98. Hering BJ, Muench KP, Schelz J, et al. The evaluation of neutral density separation utilizing Ficoll-sodium diatrizoate and Nycodenz and centrifugal elutriation in the purification of bovine and canine islet preparations. Horm Metab Res Suppl. 1990;25:57-63.
99. Balamurugan AN, Chang Y, Fung JJ, et al. Flexible management of enzymatic digestion improves human islet isolation outcome from sub-optimal donor pancreata. Am J Transplant. 2003;3:1135-1142.
100. Paraskevas S, Maysinger D, Wang R, et al. Cell loss in isolated human islets occurs by apoptosis. Pancreas. 2000;20:270-276.
101. Tsujimura T, Kuroda Y, Kin T, et al. Human islet transplantation from pancreases with prolonged cold ischemia using additional preservation by the two-layer (UW solution/perfluorochemical) cold-storage method. Transplantation. 2002;74:1687-1691.
102. Pileggi A, Molano RD, Berney T, et al. Heme oxygenase-1 induction in islet cells results in protection from apoptosis and improved in vivo function after transplantation. Diabetes. 2001;50:1983-1991.
103. Blinman TA, Gukovsky I, Mouria M, et al. Activation of pancreatic acinar cells on isolation from tissue: cytokine upregulation via p38 MAP kinase. Am J Physiol Cell Physiol. 2000;279:C1993-C2003.
104. Bottino R, Balamurugan AN, Bertera S, et al. Preservation of human islet cell functional mass by anti-oxidative action of a novel SOD mimic compound. Diabetes. 2002;51:2561-2567.
105. Robertson RP, Harmon J, Tran PO, et al. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes. 2003;52:581-587.
106. Azevedo-Martins AK, Lortz S, Lenzen S, et al. Improvement of the mitochondrial antioxidant defense status prevents cytokine-induced nuclear factor-kappaB activation in insulin-producing cells. Diabetes. 2003;52:93-101.
107. Quan N, Ho E, La W, et al. Administration of NF-kappaB decoy inhibits pancreatic activation of NF-kappaB and prevents diabetogenesis by alloxan in mice. FASEB J. 2001;15:1616-1618.
108. Giannoukakis N, Rudert WA, Trucco M, et al. Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an Ikappa B repressor. J Biol Chem. 2000;275:36509-36513.
109. Bertera S, Crawford ML, Alexander AM, et al. Gene transfer of manganese superoxide dismutase extends islet graft function in a mouse model of autoimmune diabetes. Diabetes. 2003;52:387-393.
110. Bottino R, Balamurugan AN, Tse H, et al. Response of human islets to isolation stress and the effect of antioxidant treatment. Diabetes. 2004;53:2559-2568.
111. Balamurugan AN, He J, Guo F, et al. Harmful delayed effects of exogenous isolation enzymes on isolated human islets: relevance to clinical transplantation. Am J Transp. 2005;5:2671-2681.
112. Balamurugan AN, Gu Y, Tabata Y, et al. Bioartificial pancreas transplantation at prevascularized intermuscular space: effect of angiogenesis induction on islet survival. Pancreas. 2003;26:279-285.
113. Carlsson PO, Liss P, Andersson A, et al. Measurements of oxygen tension in native and transplanted rat pancreatic islets. Diabetes. 1998;47:1027-1032.
114. Ryan EA, Paty BW, Senior PA, et al. Risks and side effects of islet transplantation. Curr Diabetes Rep. 2004;4:304-309.
115. Baidal DA, Froud T, Ferreira JV, et al. The bag method for islet cell infusion. Cell Transplant. 2003;12:809-813.
116. Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes. 2001;50:710-719.
117. Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet. 2002;360:2039-2045.
118. Pileggi A, Fenjves ES, Klein D, et al. Protecting pancreatic beta-cells. IUBMB Life. 2004;56:387-394.
119. Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J Leukoc Biol. 2005;77:587-597.
120. Markmann JF, Rosen M, Siegelman ES, et al. Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival? Diabetes. 2003;52:1591-1594.
121. De Paepe ME, Keymeulen B, Pipeleers D, et al. Proliferation and hypertrophy of liver cells surrounding islet grafts in diabetic recipient rats. Hepatology. 1995;21:1144-1153.
122. Goss JA, Schock AP, Brunicardi FC, et al. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center. Transplantation. 2002;74:1761-1766.
123. Goss JA, Goodpastor SE, Brunicardi FC, et al. Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolation center. Transplantation. 2004;77:462-466.
124. Dor Y, Brown J, Martinez OI, et al. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature. 2004;429:41-46.
125. Bonner-Weir S, Weir GC. New sources of pancreatic beta-cells. Nat Biotechnol. 2005;23:857-861.
126. Yalniz M, Pour PM. Are there any stem cells in the pancreas? Pancreas. 2005;31:108-118.
127. Zorina TD, Subbotin VM, Bertera S, et al. Recovery of the endogenous beta cell function in the NOD model of autoimmune diabetes. Stem Cells. 2003;21:377-388.